OCT 11, 2018 09:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar

Association of Biotin Ingestion with Performance of Hormone and Nonhormone Assays in Healthy Adults

C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Director of Clinical Chemistry, University of Minnesota Medical Center, and Assistant Professor of Laboratory Medicine and Pathology, University of Minnesota
    Biography
      Danni Li, PhD, DABCC, is the Director of Clinical Chemistry at the University of Minnesota Medical Center, Fairview and an Assistant Professor of Laboratory Medicine and Pathology at the University of Minnesota, Twin Cities. Dr. Li earned a BS in Chemistry from Zhejiang University in Hangzhou, China in 2002 and a PhD in Analytical Chemistry at the University of Minnesota in 2007. She completed the Clinical Chemistry Fellowship training at the Johns Hopkins University in 2009 and joined the faculty at the Johns Hopkins University in 2010. From January 2010 to August 2012, she was the Director of General Chemistry Laboratories at the Johns Hopkins Hospital and Assistant Professor of Pathology at the Johns Hopkins University. She is a member of American Association for Clinical Chemistry (AACC), and a Diplomat of American Board of Clinical Chemistry (DABCC). Dr. Li has authored over 30 peer-reviewed research articles, peer-reviewed review articles, editorial, case reports, and book chapters. In 2009, Dr. Li published a first case study from the United State on biotin interference with lab tests (i.e., PTH). She was also the first-author on a paper published in the Journal of American Medical Association (JAMA) on systematic evaluation of biotin interference on lab tests using a nonrandomized crossover trial of 6 healthy adults for 11 analytes on 37 assays over 4 major diagnostic systems. She has active research interests in high dose biotin supplement use prevalence in the United States and its impact on public health. In addition, Dr. Li has developed her independent research program in applying proteomics and lipidomics to discover plasma biomarkers in Alzheimer's disease.

    Abstract:

    High dose of biotin may cause interference with many routine clinical immunoassays and inaccurate results of some of the tests such as cardiac troponin has serious clinical complications. There is an increasing trend of high dose biotin supplement use in the US population, although the exact prevalence is still unknown. High dose of biotin supplement use may continue to increase due to its health and medical benefits and disrupt the diagnostic industry so some of the tests with serious clinical complications should be resigned to avoid biotin interference. Last but not least, more research is needed to understand the nutritional and therapeutic values of biotin.

    Learning Objectives:

    • Review mechanisms and factors that determine high dose biotin interference with lab tests
    • Describe an increasing trend of high dose biotin use and health and medical benefits
    • Explain why the continuing trend of high dose biotin use may be a game changer of the clinical diagnostic industry
    • Make a case for why more research is needed to understand nutritional and therapeutic values of biotin

    Show Resources
    Loading Comments...